These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 24193402)

  • 21. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of histologic features of toxic epidermal necrolysis.
    Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
    J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
    Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
    Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
    Wolf R; Matz H; Marcos B; Orion E
    Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea.
    Park CS; Kang DY; Kang MG; Kim S; Ye YM; Kim SH; Park HK; Park JW; Nam YH; Yang MS; Jee YK; Jung JW; Kim SH; Kim CW; Kim MY; Kim JH; Lee J; Lee JG; Kim SH; La HO; Kim MH; Park SJ; Koh YI; Lee SM; Kwon YE; Jin HJ; Kim HK; Kang HR; Choi JH;
    Allergy Asthma Immunol Res; 2019 Sep; 11(5):709-722. PubMed ID: 31332981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
    Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
    Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions.
    Lee T; Lee YS; Yoon SY; Kim S; Bae YJ; Kwon HS; Cho YS; Moon HB; Kim TB
    J Am Acad Dermatol; 2013 Sep; 69(3):407-15. PubMed ID: 23632341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children.
    Lam NS; Yang YH; Wang LC; Lin YT; Chiang BL
    J Microbiol Immunol Infect; 2004 Dec; 37(6):366-70. PubMed ID: 15599469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
    Viera MH; Perez OA; Patel JK; Jones I; Berman B
    Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS).
    Wei CH; Chung-Yee Hui R; Chang CJ; Ho HC; Yang CH; Lin YJ; Chung WH
    Eur J Dermatol; 2011; 21(6):930-7. PubMed ID: 21951554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
    Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
    J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase®.
    Shukla S; Rastogi S; Abdi SAH; Dhamija P; Kumar V; Kalaiselvan V; Medhi B
    Seizure; 2021 Oct; 91():332-338. PubMed ID: 34274893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
    Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
    Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea.
    Kang DY; Yun J; Lee SY; Koh YI; Sim DW; Kim S; Nam YH; Park JW; Kim SH; Ye YM; Park HK; Kim MH; Jee YK; Jung JW; Yang MS; Kim SH; Lee JK; Kim CW; Hur GY; Kim MY; Park SJ; Kwon YE; Choi JH; Kim JH; Kim SH; La HO; Kang MG; Park CS; Lee SM; Jeong YY; Kim HK; Jin HJ; Jeong JW; Lee J; Lee YW; Lee SE; Kim MS; Kang HR;
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):929-936.e7. PubMed ID: 32961314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
    Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases.
    Walsh S; Diaz-Cano S; Higgins E; Morris-Jones R; Bashir S; Bernal W; Creamer D
    Br J Dermatol; 2013 Feb; 168(2):391-401. PubMed ID: 23034060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
    Darlenski R; Kazandjieva J; Tsankov N
    Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.
    Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MH; Williams KM; Tian YC; Juan KC; Jan Wu YJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI
    Ann Rheum Dis; 2015 Dec; 74(12):2157-64. PubMed ID: 25115449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
    Chen J; Wang B; Zeng Y; Xu H
    Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.